AZN · story · 23 October
AstraZeneca · 6 headlines from 5 outlets, on 23 October 2026.
Outlets report that Zegfrovy (sunvozertinib), aimed at NSCLC with an EGFR exon 20 change, can now be obtained in the US after accelerated approval.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
Yahoo Finance is the largest at 8.8, ahead of Investing.com UK (8.3). Investing.com UK is the smallest at 8.3.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| Yahoo Finance | 8.8 |
| Investing.com UK | 8.3 |
| StreetInsider | 8.3 |
| Stock Titan | 8.3 |
| TipRanks | 8.3 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Yahoo Finance | 2 | +8.8 |
| Investing.com UK | 1 | +8.3 |
| StreetInsider | 1 | +8.3 |
| Stock Titan | 1 | +8.3 |
| TipRanks | 1 | +8.3 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +9.2 | US launch of lung cancer drug after approval |
| +8.3 | Zegfrovy lung cancer US launch |
| +8.3 | Sunvozertinib now on the market for NSCLC with EGFR exon 20 |
| +8.3 | Lung cancer drug available in US with 46% response |
| +8.3 | US availability of Zegfrovy announced |
| +8.3 | Zegfrovy now available for previously treated NSCLC |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.